How does ARA-290 work?

ARA-290, also called cibinetide, is an 11-amino-acid peptide taken from the tissue-protecting part of erythropoietin (EPO, a kidney hormone). This site's profile says it switches on a repair receptor without making more red blood cells. It is listed as leaving the body quickly (a short half-life). Its molecular weight is about 1,257 daltons. The largest study, a mid-stage study in 64 people, found 4 mg a day clearly grew the area of small nerve fibers in the cornea (the clear front of the eye) compared with a dummy treatment. But pain got better in every group, so the pain effect could not be told apart from the dummy treatment. A 28-day study of shots under the skin, compared with a dummy shot, reported better nerve-pain symptoms and more small nerve fibers in the cornea. A 4-week pilot in 22 people with sarcoidosis nerve damage, given through a vein, reported better symptom scores and better pain and physical function on a quality-of-life survey. It is still experimental and not FDA approved. In animal models of stroke, kidney injury, and nerve injury, an 11-amino-acid piece of EPO protected tissue and did not make more red blood cells. Those animal findings do not transfer into a counted general-repair result. This FAQ does not invent a dose. Full record at /compounds/ara-290.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of healing and recovery peptides. BPC-157, TB-500, GHK-Cu, and the tissue repair family, including what actually has human data.